Fujitsu and University of Tokyo Hospital Embark on Joint Research into AI to Aid the Fight Against Heart Disease
Early detection of heart abnormalities with electrocardiograms to promote preventative treatment
- Fujitsu and the University of Tokyo Hospital validate the effectiveness of proprietary AI technology that uses electrocardiographic data to more accurately detect patients with abnormal heart movements
- New clinical research to utilize AI with Fujitsu's proprietary waveform analysis technology (TDA: topological data analysis), which has been researched and developed jointly with the University of Tokyo Hospital
- The results of this clinical research will promote research and development of a solution that can detect abnormalities in the heart's movement at an early stage, and will contribute to the prevention of serious cases
TOKYO, Oct 11, 2021 - (JCN Newswire) - Fujitsu Limited today announced that it has started joint clinical research with the University of Tokyo Hospital to verify the effectiveness of artificial intelligence technology to estimate abnormal heart movements based on electrocardiogram(1) data. The research is planned to commence at the University of Tokyo Hospital from October 25.
|Flow of the Clinical Research|
Since December 2019, Fujitsu has been making progress with research and development of proprietary AI technology(2) in collaboration with the University of Tokyo Hospital. This research draws on data from patients that have visited the University of Tokyo Hospital to date and includes approximately 630,000 pieces of electrocardiographic data and data from approximately 140,000 cardiac ultrasounds (echocardiography)(3). This initiative has now succeeded in detecting patients with abnormal heart movements with high accuracy.
The AI will be used in clinical field research to estimate the presence or absence of abnormal heart movements based on the data of patients undergoing electrocardiographic procedures at the University of Tokyo Hospital. Patients identified by the AI as having abnormal heart movements will undergo echocardiography, and the effectiveness will be verified by comparing the results of doctors' diagnosis with the results predicted by the AI. Fujitsu will leverage this AI to detect heart disease at an early stage to prevent progression to serious illness in patients and strengthen its vision of "Healthy Living", promoting well-being for people throughout society.
This initiative will be introduced at Fujitsu ActivateNow 2021, a global event to be held from October 12 in online format.
Heart disease is the second leading cause of death in Japan (4), and electrocardiography, which detects abnormalities in the heart muscle and irregular pulses based on the waveform of electrical pulses in the heart, is widely used as a diagnostic tool to detect heart disease at an early stage. It remains difficult, however, to detect abnormalities in the shape and movement of the heart using only electrocardiograms. In medical practice, in addition to electrocardiography, doctors use a stethoscope to detect abnormal heart sounds (murmurs, arrythmia, etc.) based on the patient's description of their symptoms, followed by echocardiography to detect abnormalities in heart shape and movement. However, because echocardiographic diagnostics can only be performed in a limited number of facilities with specialized doctors and laboratory technicians, it is difficult to offer this for all patients. This makes early detection difficult, and when problems are detected, the progression of the disease may already be advanced. In the treatment of heart disease, early detection and appropriate treatment are a vital issue in medical practice.
Since December 2019, in collaboration with a research group headed by Dr. Katsuhito Fujiu, Project Associate Professor, and Dr. Issei Komuro, Professor in the Department of Cardiovascular Medicine at the University of Tokyo Hospital, Fujitsu has been engaged in research and development utilizing AI to detect heart disease from electrocardiogram data, leveraging Fujitsu's proprietary waveform analysis technology, TDA (topological data analysis) (5). Going forward, Fujitsu will work to verify the effectiveness of AI in actual medical practice to estimate the presence or absence of abnormalities in cardiac function from electrocardiogram data, and will start clinical research at the University of Tokyo Hospital.
Clinical Research Overview
Based on the electrocardiogram data of patients examined at the University of Tokyo Hospital, Fujitsu and the University of Tokyo Hospital will verify the effectiveness of detection of abnormal heart movement by AI.
From October 25, 2021 (Monday) to March 31, 2022 (Thursday) (Planned)
Department of Cardiovascular Medicine, the University of Tokyo Hospital
3. Clinical Research Activity: testing artificial intelligence to estimate abnormal heart movements
Fujitsu will install a server equipped with AI to detect abnormalities in heart movement at the University of Tokyo Hospital and connect it to a server that stores electrocardiogram data, analyze the patient's electrocardiogram, and estimate the presence or absence of abnormal heart movements. Echocardiography is performed on patients the AI predicts to have abnormal heart movements, and doctors determine whether heart disease is present.
4. Division of roles
Fujitsu: Install and operate AI-powered servers
The University of Tokyo Hospital: Input of the patient's electrocardiogram data into the AI, echocardiography if the AI suspects an abnormality, and testing the effectiveness of the AI based on the results.
Based on the results of this clinical research, Fujitsu will promote research and development of solutions that can detect abnormalities in heart motion at an early stage and contribute to the prevention of progression to serious heart disease in patients. Through its joint research with the University of Tokyo Hospital, Fujitsu will continue to actively promote research and development of AI to detect various heart diseases. Ultimately, by working to leverage the results of these efforts to contribute to the resolution of medical problems confronting society, Fujitsu will help deliver greater trust and well-being to society, and drive the development of technologies and services that promote its vision of "Healthy Living".
A record of changes in the electrical potential of the heart.
(2) Research and development on their unique AI:
Conducted in accordance with the University of Tokyo Hospital Code of Ethics.
An ultrasound scan of the chest that analyzes and images the reflected waves to check the heart's mechanical functions, including movement and shape.
(4) The second leading cause of death in Japan:
From the report of "Summary of Vital Statistics" (the Ministry of Health, Labour and Welfare).
(5) TDA (Topological Data Analysis):
A data analysis method that treats data as a set of points arranged in a space and extracts geometric information of the set.
Fujitsu's Commitment to the Sustainable Development Goals (SDGs)
The Sustainable Development Goals (SDGs) adopted by the United Nations in 2015 represent a set of common goals to be achieved worldwide by 2030. Fujitsu's purpose -- "to make the world more sustainable by building trust in society through innovation"--is a promise to contribute to the vision of a better future empowered by the SDGs.
Fujitsu is the leading Japanese information and communication technology (ICT) company offering a full range of technology products, solutions and services. Approximately 126,000 Fujitsu people support customers in more than 100 countries. We use our experience and the power of ICT to shape the future of society with our customers. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$34 billion) for the fiscal year ended March 31, 2021. For more information, please see www.fujitsu.com.
Source: Fujitsu Ltd
Sectors: Artificial Intel [AI], MedTech
Copyright ©2021 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
More Latest Release >>
MHI Publishes Integrated Report 'MHI Report 2021'
Nov 26, 2021 18:30 JST
Tokyo Gas, MC to Explore Feasibility of International Synthetic Methane Supply Chain for Carbon Neutrality
Nov 26, 2021 15:01 JST
Honda Unveils the World Premiere of Advanced Future Safety Technologies toward the Realization of its Goal for Zero Traffic Collision Fatalities by 2050
Nov 26, 2021 11:48 JST
MHI is Awarded a Major Turbomachinery Order for Ust-Luga LNG Export Plant
Nov 25, 2021 18:09 JST
MHI Thermal Systems Receives '2021 Minister of the Environment Award for Climate Action' for 'Q-ton Circulation' Air-to-Water Heat Pump
Nov 25, 2021 17:04 JST
Hirono IGCC Plant Construction Project Completed in Fukushima; Operations Launched on November 19
Nov 24, 2021 16:00 JST
Smart-City Driverless-Vehicle Pilot Project to Enhance Mobility and Healthcare in Kamakura & Fujisawa Areas
Nov 24, 2021 12:27 JST
The CBR1000RR-R Fireblade SP 30th Anniversary and New ADV350 Headline Honda's 2021 EICMA Line-up
Nov 24, 2021 09:57 JST
Transgene and NEC Announce Positive Preliminary Data from Phase I Studies of TG4050, a Novel Individualized Neoantigen Cancer Vaccine
Nov 23, 2021 11:14 JST
NEC Listed on the Dow Jones Sustainability Indices (DJSI)
Nov 23, 2021 09:02 JST
JTOWER and DOCOMO Decide to Form a Capital and Business Alliance
Nov 22, 2021 18:13 JST
Toni Bou Wins 30th Consecutive World Championship Title
Nov 22, 2021 14:38 JST
Hitachi Selected by the University of Tsukuba for its Second Proton Therapy System as a PFI Project
Nov 22, 2021 13:57 JST
Ogier, Ingrassia and TOYOTA GAZOO Racing Crowned 2021 Champions
Nov 22, 2021 12:03 JST
Eisai Receives the 'Most Liked!' IR Award at The 2021 IR Award
Nov 18, 2021 15:28 JST
Fujitsu's Blockchain Solution Applied to New Water Trading Platform to Tackle Global Water Shortages
Nov 18, 2021 11:38 JST
SDK to Raise Prices of High-Purity Gases for Electronics
Nov 18, 2021 11:30 JST
Fujitsu and RIKEN Claim 1st Place for MLPerf HPC Benchmark with Supercomputer Fugaku
Nov 18, 2021 10:34 JST
SoftBank Corp. and Honda Start Use Case Verification of Technologies to Reduce Collisions Involving Pedestrians and Vehicles Using 5G SA and Cellular V2X
Nov 17, 2021 16:22 JST
NEC to Release TIP-compliant Fully Disaggregated 400G Transponder Solution in 2022
Nov 17, 2021 13:55 JST